Table 1.
Studies investigating ILD association with specific characteristics of pSS patients.
| Authors, Year | No. of ILD Patients | Features Associated with ILD Presence in pSS | ||
|---|---|---|---|---|
| Demographic | Clinical | Laboratoristic | ||
| Shi et al., 2020 [43] | 168 | - | Higher ESSDAI | Ca 15.3 and CEA levels |
| Zhang et al., 2020 [44] | 85 | Older age, disease duration | Fever, xerophtalmia, xerostomia | WBC, CRP, and IgG levels |
| Buvry et al., 2020 [29] | 31 | - | - | Anti-Ro52 |
| Gao et al., 2018 [32] | 165 | Older age | - | RF and CRP |
| Dong et al., 2018 [28] | 206 | Older age, smoking | Dry cough, clubbing, weight loss | Anti-Ro52, higher LDH and ESR levels, and lower albumin/globulin ratio |
| Wang et al., 2018 [31] | 158 | Male sex, older age, smoking | - | ANA |
| Roca et al., 2017 [30] | 21 | Older age | Raynaud’s phenomenon, esophageal involvement | - |
| Li et al., 2015 [18] | 66 | - | - | Anti-SSA and low C3 levels |
ESSDAI—EULAR Sjögren’s syndrome disease activity index; Ca 15.3—Cancer antigen 15.3; CEA—Carcinoembryonic antigen; WBC—White blood count; CRP—C reactive protein; IgG—Immunoglobulin G; RF—Rheumatoid factor; LDH—Lactate dehydrogenase; ESR—Erythrocyte sedimentation rate; ANA—Antinuclear antibodies; C3—Complement C3 levels.